Bill Text: IN SB0282 | 2012 | Regular Session | Introduced
Bill Title: Abortion inducing drugs.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2012-01-04 - First reading: referred to Committee on Health and Provider Services [SB0282 Detail]
Download: Indiana-2012-SB0282-Introduced.html
Citations Affected: IC 16-18-2; IC 16-34-3.
Synopsis: Abortion inducing drugs. Specifies that only a physician
who meets certain conditions may administer to a pregnant woman an
abortion inducing drug, and sets forth the procedure the physician must
follow. Requires a physician who learns of an adverse event following
the use of an abortion inducing drug to report the adverse event to the
Food and Drug Administration and the medical licensing board.
Specifies that the reports of adverse events maintained by the medical
licensing board are public records. Establishes a Class A misdemeanor
for a violation concerning distribution of an abortion inducing drug and
for failure to report an adverse event.
Effective: July 1, 2012.
January 4, 2012, read first time and referred to Committee on Health and Provider
Services.
PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in
Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in this style type. Also, the word NEW will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.
Conflict reconciliation: Text in a statute in this style type or
A BILL FOR AN ACT to amend the Indiana Code concerning
health.
Chapter 3. Abortion Inducing Drugs
Sec. 1. (a) As used in this chapter, "abortion inducing drug"
means a medicine, drug, or substance prescribed or dispensed with
the intent of terminating a clinically diagnosable pregnancy with
the knowledge that the termination will, with reasonable likelihood,
cause the death of the fetus. The term includes the off-label use of
a drug known to have abortion inducing properties if the drug is
prescribed with the intent of causing an abortion.
(b) The term does not include a drug or substance that may be
known to cause an abortion when the drug is being prescribed for
another medical indication.
Sec. 2. As used in this chapter, "adverse event" means an
undesirable experience associated with the use of an abortion
inducing drug. The term includes the following incidents:
(1) Death.
(2) Life threatening occurrence.
(3) Hospitalization.
(4) Disability or permanent damage.
(5) Congenital anomaly or birth defect of the fetus.
(6) Medical intervention required to prevent permanent
impairment or damage.
Sec. 3. As used in this chapter, "drug label" means the pamphlet
or document accompanying an abortion inducing drug that:
(1) outlines the protocol tested and authorized by the federal
Food and Drug Administration;
(2) sets forth how the drug is to be used; and
(3) has been agreed upon by the drug manufacturer applying
for authorization of the drug by the federal Food and Drug
Administration.
Sec. 4. (a) It is unlawful for an individual to knowingly give, sell,
dispense, administer, prescribe, or otherwise provide an abortion
inducing drug to a pregnant woman for the purpose of inducing an
abortion or enabling an individual to induce an abortion unless the
individual meets the following requirements:
(1) Is a physician licensed under IC 25-22.5.
(2) Follows the drug label protocol for the abortion inducing
drug.
(b) Before giving, selling, dispensing, administering, prescribing,
or otherwise providing an abortion inducing drug to a pregnant
woman, a physician licensed under IC 25-22.5 shall do the
following:
(1) Examine in person the pregnant woman.
(2) Document the following information on the pregnant
woman's medical chart:
(A) The gestational age of the fetus.
(B) The intrauterine location of the fetus.
(3) Provide the following information to the pregnant woman:
(A) A copy of the drug label.
(B) The name and telephone number of the physician with
whom the treating physician has entered into a contract
described in section 5 of this chapter.
(C) The information required in IC 16-34-2-1.1.
(4) Enter into a contract as described in section 5 of this
chapter with another physician licensed under IC 25-22.5.
(c) A physician licensed under IC 25-22.5 who gives, sells,
dispenses, administers, prescribes, or otherwise provides an
abortion inducing drug to a pregnant woman shall schedule a
follow-up appointment with the woman approximately fourteen
(14) days after administration of the abortion inducing drug to:
(1) confirm that the pregnancy is terminated by conducting
ultrasound imaging; and
(2) assess the degree of bleeding experienced by the pregnant
woman.
(d) The physician described in subsection (c) shall make a
reasonable effort to ensure that the pregnant woman returns for
the follow-up appointment described in subsection (c), including
recording in the pregnant woman's medical records the date, the
time, a brief description of the efforts by the physician and the
physician's staff, and the name of the individual who performed
the efforts.
Sec. 5. (a) A physician licensed under IC 25-22.5 that gives, sells,
dispenses, administers, prescribes, or otherwise provides an
abortion inducing drug to a pregnant woman shall enter into a
contract with another physician who:
(1) is licensed under IC 25-22.5; and
(2) has admitting, gynecological, and surgical privileges at a
hospital that is designated by the treating physician to handle
complications that occur to the pregnant woman resulting
from the use of an abortion inducing drug;
to provide care for the physician's patient for any medical
complications that may arise.
(b) A physician licensed under IC 25-22.5 who enters into a
contract under subsection (a) shall make a copy of the contract
available to:
(1) the pregnant woman; or
(2) the medical licensing board of Indiana;
upon request of the pregnant woman or the board.
Sec. 6. (a) A physician licensed under IC 25-22.5 who gives, sells,
dispenses, administers, prescribes, or otherwise provides an
abortion inducing drug to a pregnant woman and who is aware of
a subsequent adverse event from the abortion inducing drug shall
report the adverse event not later than three (3) days following the
physician's knowledge of the adverse event to the following:
(1) The federal Food and Drug Administration through the
federal Medwatch reporting system.
(2) The medical licensing board of Indiana.
(b) The medical licensing board of Indiana shall maintain and
compile a report of each adverse event reported to the board under
subsection (a). A report compiled under this subsection is a public
record and is open to inspection. The report may not contain
information that personally identifies a pregnant woman who
experienced the adverse event described in subsection (a).
Sec. 7. (a) A person who intentionally, knowingly, or recklessly
violates this chapter commits an unlawful activity related to an
abortion inducing drug, a Class A misdemeanor. A pregnant
woman upon whom the drug induced abortion is performed may
not be assessed a penalty under this section.
(b) In addition to the criminal penalty under subsection (a), a
person who violates this chapter may be subject to disciplinary
sanctions under IC 25-1-9 and civil liability for wrongful death and
medical malpractice.
